Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Gauler

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Future Oncology (London, England)|December 17, 2013
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neckNadia Harbeck, Flavio Solca, Thomas C Gauler
Cancer Chemotherapy and Pharmacology|April 10, 2014
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neckVassiliki Saloura, Ezra E W Cohen, Lisa Licitra, et al.
Plos One|April 22, 2016
Circulating Tumor Cell Composition in Renal Cell CarcinomaIvonne Nel, Thomas C Gauler, Kira Bublitz, et al.
Investigational New Drugs|October 13, 2011
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursTanja Trarbach, Beate Schultheis, Thomas C Gauler, et al.
Frontiers in Oncology|May 31, 2021
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including CetuximabMichael Pogorzelski, Thomas Hilser, Saskia C Ting, et al.
Plos One|January 28, 2014
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patientsFrank Breitenbuecher, Sandra Hoffarth, Karl Worm, et al.
Clinical Lung Cancer|July 5, 2014
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patientsDaniel C Christoph, Bernadette Reyna-Asuncion, Biftu Hassan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2012
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexedDaniel C Christoph, Bernadette Reyna Asuncion, Biftu Hassan, et al.
Future Oncology (London, England)|May 7, 2014
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancerFelix Nensa, Jörg Stattaus, Bruno Morgan, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2023
HPV-associated head and neck cancer is characterized by distinct profiles of CD8<sup>+</sup> T cells and myeloid-derived suppressor cellsBenjamin A Kansy, Tim P Wehrs, Kirsten Bruderek, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Future Oncology (London, England)|December 17, 2013
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neckNadia Harbeck, Flavio Solca, Thomas C Gauler
Cancer Chemotherapy and Pharmacology|April 10, 2014
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neckVassiliki Saloura, Ezra E W Cohen, Lisa Licitra, et al.
Plos One|April 22, 2016
Circulating Tumor Cell Composition in Renal Cell CarcinomaIvonne Nel, Thomas C Gauler, Kira Bublitz, et al.
Investigational New Drugs|October 13, 2011
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursTanja Trarbach, Beate Schultheis, Thomas C Gauler, et al.
Frontiers in Oncology|May 31, 2021
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including CetuximabMichael Pogorzelski, Thomas Hilser, Saskia C Ting, et al.
Plos One|January 28, 2014
Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patientsFrank Breitenbuecher, Sandra Hoffarth, Karl Worm, et al.
Clinical Lung Cancer|July 5, 2014
Assessment of folate receptor-α and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patientsDaniel C Christoph, Bernadette Reyna-Asuncion, Biftu Hassan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2012
Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexedDaniel C Christoph, Bernadette Reyna Asuncion, Biftu Hassan, et al.
Future Oncology (London, England)|May 7, 2014
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancerFelix Nensa, Jörg Stattaus, Bruno Morgan, et al.
Cancer Immunology, Immunotherapy : CII|November 29, 2023
HPV-associated head and neck cancer is characterized by distinct profiles of CD8<sup>+</sup> T cells and myeloid-derived suppressor cellsBenjamin A Kansy, Tim P Wehrs, Kirsten Bruderek, et al.
Pageof 2